Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 319

Results For "IMI"

4535 News Found

IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
News | November 07, 2022

IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company


Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drug Approval | November 07, 2022

Lupin receives tentative approval from USFDA for Drospirenone Tablets

Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US


EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression
Clinical Trials | November 07, 2022

EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression

Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems


Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
News | November 07, 2022

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY


GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr
News | November 04, 2022

GMM Pfaudler Q2FY23 consolidated profit up at Rs. 64.98 Cr

The company has reported total income of Rs. 799.52 crores during the period ended September 30, 2022


Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr
News | November 04, 2022

Hester Biosciences Q2 FY23 consolidated profit up at Rs. 6.94 Cr

The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022


Alembic receives USFDA approval for Ketorolac Tromethamine Injection
Drug Approval | November 04, 2022

Alembic receives USFDA approval for Ketorolac Tromethamine Injection

Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients


Alembic receives USFDA approval for Mesalamine ER Capsules
Drug Approval | November 03, 2022

Alembic receives USFDA approval for Mesalamine ER Capsules

Mesalamine Extended-Release Capsules are indicated for the maintenance of remission of ulcerative colitis in adults.


Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets
Drug Approval | November 03, 2022

Glenmark receives ANDA approval for Sodium Phenylbutyrate Tablets

Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.